Senseonics Targets $100M+ 2027 Sales, But Funding and Execution Risks Loom

What happened

Senseonics management asserted that bringing commercial operations in-house has improved efficiency and supports growth, while outlining plans for new product launches and insulin pump partnerships, including a target of over $100 million in 2027 sales. This compares to 2026 guidance of $58–62 million, implying a significant acceleration, but the company still carries substantial doubt about its ability to continue as a going concern with only ~$94 million in cash and ongoing negative free cash flow. The latest DeepValue report rates the stock a WAIT with a conviction of 3.5, noting that the current price around $7 already embeds aggressive growth and margin assumptions. The efficiency claims from insourcing have yet to be proven in quarterly results, as 2025 gross margin was flattered by one-time items and SG&A is expected to rise. While the long-term target is encouraging, the investment case still hinges on smooth execution and access to capital, making a wait-and-see approach prudent.

Implication

Investors should continue to hold a wait-and-see stance, monitoring whether Senseonics can deliver on its 2026 revenue and gross margin targets before considering a position. The $100M+ 2027 sales target is consistent with the bull scenario but requires sustained 60%+ growth and margin expansion, which remains unproven. Key checkpoints include the next few quarterly results showing SG&A leverage, progress on financing without excessive dilution, and any regulatory or reimbursement developments. A failure to meet 2026 guidance or a dilutive capital raise would invalidate the thesis and could push the stock toward the attractive entry level of $4.50. Conversely, clear evidence of efficient commercialization and a lengthened runway could warrant an upgrade, but that evidence does not yet exist.

Thesis delta

The new information provides a clearer long-term revenue target of over $100 million for 2027, which aligns with the bull case but does not fundamentally change the risk profile. The thesis remains that Senseonics has a differentiated product but faces acute funding and execution challenges, and the WAIT rating stands. The delta is minimal: the news adds a forward-looking goal but no hard evidence of improved efficiency or reduced risk.